{
    "root": "1fdb4815-2990-4926-ba76-25241810489e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Precedex",
    "value": "20250314",
    "ingredients": [
        {
            "name": "DEXMEDETOMIDINE HYDROCHLORIDE",
            "code": "1018WH7F9I"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "precedex alpha 2 -adrenergic receptor agonist indicated : \u2022 sedation initially intubated mechanically ventilated adult patients treatment intensive care setting . administer precedex continuous infusion exceed 24 hours . ( 1.1 ) \u2022 sedation non-intubated adult patients prior and/or surgical procedures . ( 1.2 ) \u2022 sedation non-intubated pediatric patients aged 1 month less 18 years prior non-invasive procedures . ( 1.2 )",
    "contraindications": "\u2022 individualize titrate precedex dosing desired effect . ( 2.1 ) \u2022 administer precedex using controlled infusion device . ( 2.1 ) \u2022 200 mcg/50 ml , 400 mcg/100 ml single-dose bottles require dilution prior . ( 2.4 ) \u2022 adult intensive care unit sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion 0.2 0.7 mcg/kg/ hour . ( 2.2 ) \u2022 adult procedural sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion initiated 0.6 mcg/kg/ hour titrated achieve desired effect doses ranging 0.2 1 mcg/kg/ hour . ( 2.2 ) \u2022 sedation pediatric patients non-invasive procedures : patients 1 month less 2 years old initiate 1.5 mcg/kg 10 minutes followed maintenance infusion 1.5 mcg/kg/ hour titrated achieve desired effect ranging 0.5 1.5 mcg/kg/ hour ; patients 2 less 18 years old initiate 2.0 mcg/kg 10 minutes followed maintenance infusion 1.5 mcg/kg/ hour titrated achieve desired effect ranging 0.5 1.5 mcg/kg/ hour . ( 2.2 ) \u2022 alternative doses : recommended patients 65 years age awake fiberoptic intubation patients . ( 2.2 )",
    "warningsAndPrecautions": "store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . [ usp controlled room temperature . ] product discolored precipitate matter present . precedex ( dexmedetomidine hydrochloride 0.9 % sodium chloride ) injection ( 4 mcg/ml ) clear colorless . strength based dexmedetomidine base . discard unused portion . unit sale concentration ndc 0409-4596-20 tray 20 single\u2011dose clear glass bottles 200 mcg/50 ml ( 4 mcg/ml ) ndc 0409-0155-02 tray 10 single\u2011dose clear glass bottles 400 mcg/100 ml ( 4 mcg/ml )",
    "adverseReactions": "none .",
    "indications_original": "PRECEDEX is a alpha 2 -adrenergic receptor agonist indicated for: \u2022 Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. ( 1.1 ) \u2022 Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 ) \u2022 Sedation of non-intubated pediatric patients aged 1 month to less than 18\u00a0years prior to and during non-invasive procedures. ( 1.2 )",
    "contraindications_original": "\u2022 Individualize and titrate PRECEDEX dosing to desired clinical effect. ( 2.1 ) \u2022 Administer PRECEDEX using a controlled infusion device. ( 2.1 ) \u2022 The 200 mcg/50 mL, and 400 mcg/100 mL single-dose bottles do not require further dilution prior to administration. ( 2.4 ) \u2022 For Adult Intensive Care Unit Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/ hour . ( 2.2 ) \u2022 For Adult Procedural Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1\u00a0mcg/kg/ hour . ( 2.2 ) \u2022 For Sedation of Pediatric Patients During Non-invasive Procedures : Patients 1 month to less than 2 years old initiate at 1.5 mcg/kg over 10 minutes followed by a maintenance infusion of 1.5 mcg/kg/ hour and titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/ hour ; patients 2 to less than 18 years old initiate at 2.0 mcg/kg over 10 minutes followed by a maintenance infusion of 1.5 mcg/kg/ hour and titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/ hour . ( 2.2 ) \u2022 Alternative Doses : Recommended for patients over 65 years of age and awake fiberoptic intubation patients. ( 2.2 )",
    "warningsAndPrecautions_original": "Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F). [See USP Controlled Room Temperature.]\n                  Do not use if product is discolored or if precipitate matter is present.\n                  PRECEDEX (dexmedetomidine hydrochloride in 0.9% Sodium Chloride) injection (4 mcg/mL) is clear and colorless. The strength is based on the dexmedetomidine base. Discard unused portion.\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Concentration\n                              \n                           \n                        \n                        \n                           \n                              \n                                 NDC 0409-4596-20\n                              \n                              Tray of 20 single\u2011dose clear glass bottles\n                           \n                           \n                              200 mcg/50 mL\n                              (4 mcg/mL)\n                           \n                        \n                        \n                           \n                              \n                                 NDC 0409-0155-02\n                              \n                              Tray of 10 single\u2011dose clear glass bottles\n                           \n                           \n                              400 mcg/100 mL\n                              (4 mcg/mL)",
    "adverseReactions_original": "None."
}